Noelia Tarazona, Coordinator of Cancer Care at INCLIVA Biomedical Research Institute in Valencia, Spain, shared on LinkedIn:
“I’m delighted to share our latest work, now published in Clinical Cancer Research.
We investigated the clinical value of molecular residual disease (MRD) and the optimal timing of circulating tumor DNA (ctDNA) assessment after definitive chemoradiotherapy for locally advanced head and neck cancer.
My sincere thanks to everyone who contributed to this study, especially Guardant Health for their collaboration, and Gema Bruixola and Jorge Martín Arana, who led the work.
Title: Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment
Authors: Gema Bruixola, Jorge Martín-Arana, Francisco Gimeno-Valiente, Franz Villarroel-Espindola, Clara Alfaro-Cervelló, Delfina Dualde, Nuria Grimalt, Miguel García Bartolomé, Alonso García-Márquez, Belén Iglesias-Martinez,
Francisco Martínez-Picó, Belén Martínez-Castedo, Blanca García-Micó, Daniel González Camblor, Maria Eugenia Iglesias, Vicente Escorihuela García, María Maroñas, Jim Hayes, Andrés Cervantes, Noelia Tarazona.
Read the article: Clinical Cancer Research.”
- After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer
- J. Robert Oppenheimer: Throat Cancer Diagnosis and Cause of Death
